Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
Darovasertib data are promised for the last week of March.
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The company buys in a PI3Kα and mTOR combo.
Gilead opting against IDE397 is still good news for Ideaya.
Progression-free and overall survival data from Companion-002 are due this quarter.
